AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Deoxyguanosine kinase, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q16854

UPID:

DGUOK_HUMAN

Alternative names:

Deoxyadenosine kinase, mitochondrial

Alternative UPACC:

Q16854; P78532; Q16759; Q4ZG09; Q7L1W9; Q96BC1

Background:

Deoxyguanosine kinase, mitochondrial, also known as Deoxyadenosine kinase, mitochondrial, plays a pivotal role in mitochondrial DNA synthesis. It phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, crucial for mtDNA replication in non-replicating cells. Its highest efficiency is with deoxyguanosine, and it also phosphorylates certain nucleoside analogs.

Therapeutic significance:

This protein is linked to diseases such as Mitochondrial DNA depletion syndrome 3, characterized by progressive liver failure and neurologic abnormalities, and Progressive external ophthalmoplegia with mitochondrial DNA deletions. Understanding the role of Deoxyguanosine kinase could open doors to potential therapeutic strategies for these mitochondrial disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.